SCHEMBL5092265

SCHEMBL5092265

C=CCn1c(C2CC2)nnc1C12CC3CC(CC(C3)C1)C2

nearest known ligand 0.52

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 6/20 0.43
KDM4E B2RXH2 1/20 0.41
POLB P06746 2/20 0.40
GAA P10253 2/20 0.36
CYP3A4 P08684 1/20 0.36
CYP2C9 P11712 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
TDP1 Q9NUW8 1/20 0.35
HSD17B1 P14061 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.34
RAB9A P51151 1/20 0.34
TSHR P16473 1/20 0.33
ALDH1A1 P00352 2/20 0.32
MAPT P10636 1/20 0.32
MEN1 O00255 1/20 0.32
KMT2A Q03164 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5098640 0.81 HSD11B1 (0.60) HSD11B1POLBGAACYP3A4SMN1; SMN2
SCHEMBL5095947 0.79 HSD11B1 (0.44) HSD11B1GAACYP3A4CYP2C9SMN1; SMN2
SCHEMBL5097998 0.78 HSD11B1 (0.65) HSD11B1POLBGAASMN1; SMN2HSD17B1
SCHEMBL5097991 0.77 HSD11B1 (0.46) HSD11B1GAASMN1; SMN2HSD17B1L3MBTL1
SCHEMBL5098636 0.77 HSD11B1 (0.68) HSD11B1GAASMN1; SMN2HSD17B1L3MBTL1
SCHEMBL5095935 0.77 HSD11B1 (0.49) HSD11B1GAASMN1; SMN2HSD17B1RAB9A
SCHEMBL5092047 0.75 HSD11B1 (0.72) HSD11B1GAASMN1; SMN2HSD17B1RAB9A
SCHEMBL5098790 0.74 HSD17B10 (0.46) HSD11B1KDM4EGAASMN1; SMN2L3MBTL1
SCHEMBL5098546 0.72 HSD11B1 (0.51) HSD11B1KDM4EGAASMN1; SMN2HSD17B1
SCHEMBL5104767 0.71 HSD11B1 (0.46) HSD11B1GAAHSD17B1RAB9AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7329683-B2 11-β-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia MERCK & CO., INC. (US) 2008-02-12 US disclosed
US-7329683-B2 11-β-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia MERCK & CO., INC. (US) 2008-02-12 US disclosed
US-7329683-B2 11-β-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia MERCK & CO., INC. (US) 2008-02-12 US disclosed
US-20050070720-A1 11-Beta-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia MERCK SHARP & DOHME CORP. 2005-03-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050070720-A1 11-Beta-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia HSD11B1, HSD17B1, HSD11B2 HSD11B1 1/4885KDM4E 1589/4885POLB 2988/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.